Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810864 | 0.73 | CA1 (0.50) | CA1CA2 | |
| SCHEMBL3107462 | 0.68 | F2 (0.46) | CA1CA2 | |
| SCHEMBL1163838 | 0.66 | CA12 (0.34) | CA1CA2 | |
| SCHEMBL10789031 | 0.65 | CA2 (0.52) | CA1CA2 | |
| SCHEMBL25708327 | 0.65 | CA2 (0.52) | CA1CA2 | |
| SCHEMBL19840567 | 0.65 | CA12 (0.31) | CA2 | |
| SCHEMBL19019137 | 0.64 | CA1 (0.50) | CA1CA2 | |
| SCHEMBL1618240 | 0.62 | CA2 (0.48) | CA1CA2 | |
| SCHEMBL627731 | 0.62 | CA2 (0.48) | CA1CA2 | |
| SCHEMBL319638 | 0.62 | CA2 (0.48) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419990-B2 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060128963-A1 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-06-15 | — | — | US | disclosed |
| EP-1648457-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009950-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128963-A1 | Piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC1R | CA1 4884/4885CA2 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.